JP2023518044A - Nlrp3モジュレーター - Google Patents
Nlrp3モジュレーター Download PDFInfo
- Publication number
- JP2023518044A JP2023518044A JP2022555714A JP2022555714A JP2023518044A JP 2023518044 A JP2023518044 A JP 2023518044A JP 2022555714 A JP2022555714 A JP 2022555714A JP 2022555714 A JP2022555714 A JP 2022555714A JP 2023518044 A JP2023518044 A JP 2023518044A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- acceptable salt
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Amplifiers (AREA)
- Burglar Alarm Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025033957A JP7892820B2 (ja) | 2020-03-16 | 2025-03-04 | Nlrp3モジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062990363P | 2020-03-16 | 2020-03-16 | |
| US62/990,363 | 2020-03-16 | ||
| PCT/US2021/022397 WO2021188450A1 (en) | 2020-03-16 | 2021-03-15 | Nlrp3 modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025033957A Division JP7892820B2 (ja) | 2020-03-16 | 2025-03-04 | Nlrp3モジュレーター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518044A true JP2023518044A (ja) | 2023-04-27 |
| JP2023518044A5 JP2023518044A5 (cg-RX-API-DMAC7.html) | 2024-03-18 |
Family
ID=77747550
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555714A Ceased JP2023518044A (ja) | 2020-03-16 | 2021-03-15 | Nlrp3モジュレーター |
| JP2025033957A Active JP7892820B2 (ja) | 2020-03-16 | 2025-03-04 | Nlrp3モジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025033957A Active JP7892820B2 (ja) | 2020-03-16 | 2025-03-04 | Nlrp3モジュレーター |
Country Status (16)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| WO2021009567A1 (en) | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CA3175729A1 (en) | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| CN117247393A (zh) * | 2022-06-17 | 2023-12-19 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| WO2025255532A1 (en) * | 2024-06-07 | 2025-12-11 | Zomagen Biosciences Ltd | Combination therapies |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019034696A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| JP2019518071A (ja) * | 2016-04-18 | 2019-06-27 | アイエフエム トレ インコーポレイテッド | Nlrp活性に関連する状態を処置するための化合物および組成物 |
| US20190192478A1 (en) * | 2016-01-25 | 2019-06-27 | Galderma Research & Development | Nlrp3 inhibitors for the treatment of inflammatory skin disorders |
| JP2020505381A (ja) * | 2017-01-23 | 2020-02-20 | ジェネンテック, インコーポレイテッド | インターロイキン−1活性の阻害剤としての化学化合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2119705A1 (en) * | 2008-05-14 | 2009-11-18 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor |
| ES2668834T3 (es) * | 2008-09-08 | 2018-05-22 | Merck Serono Sa | Pirimidinas macrociclicas como inhibidores de proteína quinasas |
| CN107207431B (zh) * | 2015-01-13 | 2021-02-09 | 维夫雷昂生物科学有限责任公司 | Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途 |
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| BR112018016671A2 (pt) | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| US11840543B2 (en) * | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| CN110914256A (zh) * | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| ES2927851T3 (es) | 2017-10-17 | 2022-11-11 | Novartis Ag | Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| US20200399242A1 (en) * | 2018-03-02 | 2020-12-24 | Inflazome Limited | Novel compounds |
| MA53172A (fr) * | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| US20230011652A1 (en) | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| WO2021009567A1 (en) | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CA3175729A1 (en) | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
-
2021
- 2021-03-15 CA CA3175729A patent/CA3175729A1/en active Pending
- 2021-03-15 BR BR112022018480A patent/BR112022018480A2/pt not_active Application Discontinuation
- 2021-03-15 CN CN202180035570.2A patent/CN115605209B/zh active Active
- 2021-03-15 PH PH1/2022/552447A patent/PH12022552447A1/en unknown
- 2021-03-15 WO PCT/US2021/022397 patent/WO2021188450A1/en not_active Ceased
- 2021-03-15 MX MX2022011576A patent/MX2022011576A/es unknown
- 2021-03-15 JP JP2022555714A patent/JP2023518044A/ja not_active Ceased
- 2021-03-15 KR KR1020227035334A patent/KR20220154165A/ko active Pending
- 2021-03-15 AU AU2021237477A patent/AU2021237477A1/en active Pending
- 2021-03-15 EP EP21770604.3A patent/EP4121059A4/en active Pending
- 2021-03-15 IL IL296488A patent/IL296488A/en unknown
- 2021-03-15 AR ARP210100650A patent/AR121573A1/es unknown
- 2021-03-15 US US17/202,047 patent/US11603375B2/en active Active
- 2021-03-16 TW TW110109276A patent/TWI901652B/zh active
-
2022
- 2022-09-15 CL CL2022002531A patent/CL2022002531A1/es unknown
- 2022-10-12 CO CONC2022/0014499A patent/CO2022014499A2/es unknown
-
2023
- 2023-02-02 US US18/163,680 patent/US20230183258A1/en not_active Abandoned
- 2023-10-09 US US18/483,397 patent/US20240101571A1/en not_active Abandoned
-
2025
- 2025-03-04 JP JP2025033957A patent/JP7892820B2/ja active Active
- 2025-08-26 US US19/310,713 patent/US20260200935A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190192478A1 (en) * | 2016-01-25 | 2019-06-27 | Galderma Research & Development | Nlrp3 inhibitors for the treatment of inflammatory skin disorders |
| JP2019518071A (ja) * | 2016-04-18 | 2019-06-27 | アイエフエム トレ インコーポレイテッド | Nlrp活性に関連する状態を処置するための化合物および組成物 |
| JP2020505381A (ja) * | 2017-01-23 | 2020-02-20 | ジェネンテック, インコーポレイテッド | インターロイキン−1活性の阻害剤としての化学化合物 |
| WO2019034696A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
Also Published As
| Publication number | Publication date |
|---|---|
| US11603375B2 (en) | 2023-03-14 |
| CA3175729A1 (en) | 2021-09-23 |
| MX2022011576A (es) | 2022-10-18 |
| CN115605209A (zh) | 2023-01-13 |
| WO2021188450A1 (en) | 2021-09-23 |
| BR112022018480A2 (pt) | 2022-11-29 |
| JP7892820B2 (ja) | 2026-07-21 |
| US20210292336A1 (en) | 2021-09-23 |
| AR121573A1 (es) | 2022-06-15 |
| US20240101571A1 (en) | 2024-03-28 |
| US20260200935A1 (en) | 2026-07-16 |
| EP4121059A1 (en) | 2023-01-25 |
| PH12022552447A1 (en) | 2024-01-03 |
| TW202200584A (zh) | 2022-01-01 |
| AU2021237477A1 (en) | 2022-10-13 |
| US20230183258A1 (en) | 2023-06-15 |
| CL2022002531A1 (es) | 2023-03-31 |
| TWI901652B (zh) | 2025-10-21 |
| CN115605209B (zh) | 2024-12-17 |
| IL296488A (en) | 2022-11-01 |
| CO2022014499A2 (es) | 2023-02-16 |
| KR20220154165A (ko) | 2022-11-21 |
| EP4121059A4 (en) | 2023-12-13 |
| JP2025102771A (ja) | 2025-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7595642B2 (ja) | Nlrp3モジュレーター | |
| JP2024529839A (ja) | Nlrp3モジュレーター | |
| CN115605209B (zh) | Nlrp3调节剂 | |
| JP7723652B2 (ja) | 多発性硬化症(MS)の治療のためのNLPR3モジュレーターとしてのN-((1,2,3,5,6,7-ヘキサヒドロ-s-インダセン-4-イル)カルバモイル)-4,5,6,7-テトラヒドロベンゾフラン-2-スルホンアミド誘導体および関連化合物 | |
| AU2020218267A1 (en) | TYK2 pseudokinase ligands | |
| DE69813605T2 (de) | Benzofuranderivate | |
| EA049038B1 (ru) | Модуляторы nlrp3 | |
| WO2025059069A1 (en) | Nlrp3 modulators | |
| EA051075B1 (ru) | Модуляторы nlrp3 | |
| EA048687B1 (ru) | ПРОИЗВОДНЫЕ N-((1,2,3,5,6,7-ГЕКСАГИДРО-s-ИНДАЦЕН-4-ИЛ)КАРБАМОИЛ)-4,5,6,7-ТЕТРАГИДРОБЕНЗОФУРАН-2-СУЛЬФОНАМИДА И СВЯЗАННЫЕ СОЕДИНЕНИЯ В ВИДЕ МОДУЛЯТОРОВ NLPR3 ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221128 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221118 |
|
| RD12 | Notification of acceptance of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7432 Effective date: 20221128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240307 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240307 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250116 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250205 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20250623 |